The Characteristics of initial public offering for innovative small and medium-sized firms: the case of young french bio/medtech firms

Les modalités d’introduction en bourse des PME-ETI innovantes:le cas des jeunes pépites bio/medtech françaises

Evelyne Poincelot () and Dominique Poincelot ()
Additional contact information
Evelyne Poincelot: CREGO - Centre de Recherche en Gestion des Organisations (EA 7317) - Université de Haute-Alsace (UHA) - Université de Haute-Alsace (UHA) Mulhouse - Colmar - UB - Université de Bourgogne - UBFC - Université Bourgogne Franche-Comté [COMUE] - UFC - Université de Franche-Comté - UBFC - Université Bourgogne Franche-Comté [COMUE]
Dominique Poincelot: CREGO - Centre de Recherche en Gestion des Organisations (EA 7317) - Université de Haute-Alsace (UHA) - Université de Haute-Alsace (UHA) Mulhouse - Colmar - UB - Université de Bourgogne - UBFC - Université Bourgogne Franche-Comté [COMUE] - UFC - Université de Franche-Comté - UBFC - Université Bourgogne Franche-Comté [COMUE]

Post-Print from HAL

Abstract: The various government measures in favor of innovative SMEs, the number of biotechnology firms listed on the stock exchange over the last ten years, the characteristics of their pre-introduction financing are different factors that justify a particular interest for these firms and their methods of introduction (discount, float, quotation procedure). Different tests of mean difference have significant results. Comparing with a control sample, we found that SME in this sector are listed on the stock exchange faster, by making greater use of the open-price offer procedure (OPO) and are subject to greater prior financing by financial stockholders. Although the ownership of the capital and the disengagement of the financial stockholders, who are also the main shareholders, are larger, we do not see any significant difference with the control firms. For these biotech companies, the disengagement of financial shareholders is characterized more by a dilution effect of their participation because none sells securities and does not wish to subscribe for new shares at the time of the introduction. This article has also made it possible to characterize, in depth, the firms in this sector, in particular the financial shareholders participating in the financing. The results obtained by the regressions do not reveal any significant variables that may explain the discount or the size of the dilution relative to the float rate.

Keywords: Innovative SMEs; Biotechnology firms; Pme innovante; Société de biotechnologie; IPO; introduction en bourse (search for similar items in EconPapers)
Date: 2017-03-30
References: Add references at CitEc
Citations:

Published in Financing and governance of innovative companies, CREGO (Centre de Recherche en Gestion des Organisations), RITM (Réseaux Innovation Territoires et Mondialisation), Mar 2017, Dijon, France

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01799871

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().